

**Medicinal chemistry** 

Open Access

# Drug Targets for Cancer Treatment: An Overview

Shashank Kumar<sup>1</sup>, Mohammad Kaleem Ahmad<sup>1</sup>, Mohammad Waseem<sup>1</sup> and Abhay K Pandey<sup>2\*</sup>

<sup>1</sup>Molecular and Cell Biology Laboratory, Department of Biochemistry, King Georges Medical university, Lucknow-226003, India <sup>2</sup>Department of Biochemistry, University of Allahabad, Allahabad-211002, India

#### Abstract

Cancer is one of the major cause of death worldwide. Malignant cells display metabolic changes, when compared to normal cells, because of both genetic and epigenetic alterations. Number of drugs being used for the cancer treatment follows different mechanisms of action. Therapeutic strategies include targeting of drugs at specific genes or proteins/enzymes found in cancer cells or the internal tissue environment which contributes to growth and survival of these cells. Targeted therapy is often used along with chemotherapy and other treatments to restrict the growth and spread of cancer cells. During the past few decades, targeted therapy has emerged as a promising approach for the development of selective anticancer agents. There is a class of targeted therapy drugs called angiogenesis inhibitors which focus on blocking the development of new blood vessels in tumor tissues. In addition, anticancer drugs also include DNA intercalators, DNA synthesis inhibitors, transcription regulators, enzyme inhibitors etc. This review focuses on major classes of anticancer drug targets and their therapeutic importance.

**Keywords:** Anticancer drug targets; Angiogenesis; Gene regulation; Enzyme; Microtubules

#### Introduction

Cancer is the second leading cause of death in Europe and America. Tremendous resources are being invested all around the world for developing preventive, diagnostic, and therapeutic strategies for cancer [1]. Several pharmaceutical companies and government/ non-government organizations are involved in the discovery and development of anticancer agents [2]. Identification of novel cytotoxic compounds has led to the development of anticancer therapeutics for several decades. Boom of knowledge in molecular sciences, genomics and proteomics has also helped in creating new potential drug targets. This has changed the paradigms of anticancer drug discovery toward molecularly targeted therapeutics. There are unique challenges and opportunities in discovery of anticancer drug delivery which might reflect at each stage of the drug development process [3]. Cancer is primarily a disease of uncontrolled cell division, thus identification of anti-proliferative compounds and their effects on regression of tumor size are the main aims for therapeutic discovery. For this purpose murine models of cancer were developed and several clinically important anticancer compounds were identified [1]. Differentiated result outputs among fast growing and slow growing tumors led investigators to modify the screening protocols to include a variety of cell lines and tumor types. The rationale that cancer cells are more likely to be replicating than normal cells makes the basis for targeting cell division process by most of the chemotherapeutics. Unfortunately significant toxicity is associated with chemotherapeutics as they lack specific action [1-3].

Double-helical DNA consists of two complementary strands running anti-parallel having sugar-phosphate polydeoxyribonucleotide backbone associated with specific hydrogen bonding between nucleotide bases [4]. In a given DNA sequence difference in chemical feature of the molecular surfaces in either groove forms the basis for molecular recognition by small molecules and proteins. B-form of the DNA i.e. biologically relevant double helix is characterized by a shallow wide major groove and a deep narrow minor groove [5]. DNA replication, transcription and protein synthesis are the major steps in cell growth and division. Being carrier of genetic information as well as central to tumorigenesis and pathogenesis, DNA is a major target for drug development. There is always a challenge for drug to achieve maximum specific DNA binding affinity. The other thing that needs consideration is that drug should not affect cellular and nuclear transport activity of the normal cells. Some of the most effective anticancer agents that target DNA are known to produce significant survival rate in cancer patients when used in combination with drugs having different mechanisms of action [6]. Besides DNA, RNA, enzymes and other proteins also contributes as major targets for anticancer drug development [7]. Structures of some anticancer drugs are depicted in Figure 1. In this review we have tried to discuss some molecular aspects of anticancer drug mechanisms.

#### **Angiogenesis Inhibitors**

Angiogenesis (AG) is the process by which tumour develops new blood supply (neovascularisation) for the growth and metastasis. Small tumours can obtain oxygen and nutrients by diffusion but as they become enlarged they need to develop new blood vessels for the fulfillment of required nutrients for growth, invasion and metastasis. Different anti- and pro-angiogenic factors are involved in the development of blood vessels in a complex equilibrium [8]. In physiological processes such as wound healing this equilibrium may go in favor of angiogenesis by inflammation or hypoxia. But on the other hand it may be the part of the pathological process in cancer or other chronic inflammatory diseases. Vascular endothelial growth factor (VEGF), angiogenin, transforming growth factor- $\beta$  (TGF- $\beta$ ) and fibroblast growth factor (FGF) are some pro-angiogenic factors that are released in tumor associated angiogenesis which in turn induces the proliferation, migration and invasion of endothelial cells in new vascular structures [8]. Platelet derived growth factor receptor and cell adhesion molecules (e.g., integrins) play important role in the process of angiogenesis. Oxygen deprivation, oncogenic mutations, inflammation and mechanical stress are the stimulus that initiates growth of new vessels in tumor (angiogenic switch). This leads to vascularisation

\*Corresponding author: Abhay K. Pandey, Department of Biochemistry, University of Allahabad, Allahabad-211002, India, E-mail: akpandey23@rediffmail.com

Received February 24, 2015; Accepted March 17, 2015; Published March 19 2015

Citation: Kumar S, Ahmad MK, Waseem M, Pandey AK (2015) Drug Targets for Cancer Treatment: An Overview. Med chem 5: 115-123. doi:10.4172/2161-0444.1000252

**Copyright:** © 2015 Kumar S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



and expression of pro-angiogenic factors in tumor [8]. Some of the angiogenesis inhibitors and their mode of action are shown in Table 1.

VEGF signaling through its receptor tyrosine kinase is the major inducer of angiogenesis. VEGFR-1, 2, and 3 are the three receptor tyrosine kinases of VEGFR family which mediate the angiogenic effect [9]. In endothelial cells stimulation of VEGFRs, other tyrosine kinases, G-proteins and serine/threonine kinases cause massive activation of signaling pathways. Src homology 2 (SH2) and b-cell (Shb) protein act as adapter molecules in VEGFR mediated signaling in angiogenesis. Endothelial cell migration, proliferation, and survival are the important processes involved in angiogenesis. These event takes place by the activation of PI3K (phosphatidylinositol 3-kinase) and Akt/PKB (serine threonine kinase/protein kinase B), by virtue of Shb protein interaction with VEGFR-2 phosphorylation site. For last three decades AG has been taken as an appealing target for anticancer drugs [9]. Till know about thirty AG inhibitors are in clinical trials and some of them have been approved for the treatment of malignancy. AG inhibitors play role as cytostatic rather than cytotoxic drugs. The anti-angiogenic drugs have capability to reduce the production of pro-angiogenic factors as well as their binding efficacy to respective receptors which results into their blockage of action [8,9].

## **DNA Intercalators and Groove Binding Agents**

Intercalation and groove binding are the major mechanisms underlying drug-DNA interaction. Insertion of a planar molecule between DNA base pairs is known as intercalation which results

| Name                       | Mode of Action                                                                                      | References |
|----------------------------|-----------------------------------------------------------------------------------------------------|------------|
| Angiostatin K13            | Inhibitor of endothelial cell growth and angiogenesis.                                              | [10]       |
| DLaDifluoromethylornithine | Inhibition of ornithine decarboxylase (ODC) and blocks angiogenesis                                 | [11]       |
| Endostatin                 | Inhibits endothelial cell proliferation; Potent inhibitor of angiogenesis and tumor growth as well. | [12]       |
| Fumagillin                 | Inhibitor of endothelial cell proliferation and angiogenesis.                                       | [13]       |
| Genistein                  | Down regulates the transcription of genes involved in controlling angiogenesis.                     | [14]       |
| Minocycline                | Inhibits endothelial cell proliferation and angiogenesis.                                           | [15]       |
| Staurosporine              | Blocks angiogenesis by inhibition of up regulated VEGF expression in tumor cells.                   | [16]       |
| (±)Thalidomide             | Inhibits biosynthesis of tumor necrosis factor $\alpha$ (TNF $\alpha$ ); inhibits angiogenesis.     | [17]       |

Table 1: Angiogenesis inhibitors and their mode of action as anticancer agent.

in the reduction of lengthening and helical twist of the DNA [18]. Approximately 4 kcal per mol free energy is used to establish the intercalation cavity. Some favorable contributions viz., hydrophobic, ionic, hydrogen bonding, and vander Waals forces are also involved [18]. DNA intercalating agents may be divided into mono (e.g. ellipticine, actinomycins and fused quinoline compounds) and bi/ poly (e.g. ditercalinium and echinomycin) functional intercalating molecules. The two intercalating units (usually cationic) in bifunctional intercalators are separated by a spacer chain that must be long enough to allow double intercalation [19]. Recognition and function of DNAassociated proteins (polymerases, topoisomerases, transcription factors and DNA repair systems) are disturbed by DNA intercalating agents. Bi/tricyclic fused or non-fused ring structures have been traditionally used as DNA intercalating agents. They are known to be used as antimalarial, antibiotic, antitumor and antineoplastic agents. The intercalators may be toxic or non toxic depending on the presence/absence of various functional groups viz., basic, cationic, or electrophilic required for genotoxicity [20,21]. Groove binding molecules (usually crescent-shaped) unlike intercalators bind to the minor groove of DNA as a standard lock-and-key model and do not induce large conformational changes in DNA. Here, for the creation of binding site, cost of free energy is not required and the associations are stabilized by intermolecular interactions [22]. DNA intercalators are less sequence selective and show a preference for G-C regions. On the other hand groove binding molecules are more sequence selective and do not show G-C region preference [23]. Intercalators and groove binders have proven clinical utility both as anticancer and antibacterial agents. For example mitomycin and anthracyclines are exemplified both as DNA crosslinker as well as groove-binding molecules [24]. Table 2 shows some more example of DNA intercalators used as anticancer agents.

## **DNA Synthesis Inhibitors**

It is well established that without purines, pyrimidines, serine, and methionine the de novo synthesis of DNA in mammalian cells can not be possible. Folates belong to the family of B9 vitamins that are essential to mammalian cells. Folic acid is not a naturally occurring folate, it is composed of a pteridine ring, para-aminobenzoic acid (pABA) and glutamate [33]. In cells folic acid undergoes reduction process mediated by dihydrofolate reductase (DHFR) which ultimately leads to production of folate polyglutamates. These polyglutamates serve as one-carbon donors in de novo synthesis of purines, thymidylate, and polyamines [34]. The understanding of the role of folate derivatives in humans has led to the identification and development of antifolates as therapeutic agents. This idea got support from the observation of serum folate deficiency among patients with acute leukemia in the early 1940s leading to new postulation that acute leukaemia might be the result of folate deficiency [33]. Ribonucleotide reductase (RNR) is an enzyme responsible for the de novo conversion of ribonucleoside diphosphate (NDP) to deoxyribonucleoside diphosphate and also

regulates the supply of intracellular dNTP [35]. The consequences of imbalance in the substrates for DNA synthesis may lead to mutagenesis and cell death. Thus maintenance of a balanced dNTP pool is a fundamental cellular function by RNR shows its importance in cell survival. Because of this activity differential expression of RNR is tightly regulated during cell cycle [36,37]. Aberrant replication forks, activation of S-phase checkpoint, and cell-cycle arrest are the some key goals that might be achieved by targeted inhibition of RNR [37]. RNR is expressed at relatively low level in normal cells while in cancer cells its expression level is very high for maintaining high dNTP pools required for DNA synthesis and proliferation. Using a structure and mechanism based approach scientist have designed and developed novel class of RNR inhibitors with potential clinical use. Recently COH29, an RNR inhibitor was discovered that showed activity in tissue culture and human tumor xenografts in mice [38]. S-phase arrest was observed in cell cultures treated with COH29 which is consistent with inhibition of RNR and its established role of catalyzing the rate-limiting step in dNTP synthesis and therefore DNA synthesis [39,40]. Novel binding pocket in RNR have been identified which is located on such a position that makes it potentially capable of multiple functional and biologically relevant effects. Gemcitabine (2',2'-difluoro-2'-deoxycytidine, dFdC) is metabolized intracellularly to 5'diphosphate (dFdCDP). It is another potent inhibitor of ribonucleotide reductase and a very promising anticancer drug [41]. Several DNA synthesis inhibitors have been enumerated along with their mode of action in Table 3.

## **Transcription Regulators**

In all living cells transcription is required for the growth and survival. However, tumor cells require excess levels of transcription, including ribosomal RNA and mRNA transcription by RNA polymerase I and RNA polymerase II respectively. Mutations are responsible for the enhanced transcription in cancer cells. DNA transcription is dependent on the spatially and temporally coordinated interaction between transcriptional machinery and transcriptional regulatory components. Different transcription factors (TFs) have been reported to associate with cancer. Transcription deregulation can occur by aberrant activation, repression, temporal/spatial dyscoordination, structural changes including mutations, translocations, and fusion. Dysregulation of transcriptional and thereby post-transcriptional processes contributes to cancer initiation [51]. The TF nuclear factor (NF)-kB is a family of five reticuloendotheliosis (REL) proteins. The protein influences gene transcription that allows its translocation into the nucleus. Its inhibition sequesters the complex (NF-kB and its inhibitor IkBa) in the cytoplasm in an inactive conformation. Activation of NF-kB transcription factor may lead to IkBa degradation. NF-kB has been known to be active constitutively in several cancer types. It is associated with the regulation of cell survival, cell proliferation, invasion, metastasis and apoptosis inhibition. Thus inhibition of NFkB transcription factor may result into retarded tumor formation [51]. Targeting of a TF might inhibit several cancer related genes, since

| Name                                              | Mode of Action                                                                                                  | References |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|------------|
| Bleomycin                                         | Inhibits DNA synthesis; causes cleavage at specific base sequences. Induces apoptosis and inhibit angiogenesis. | [25]       |
| Carboplatin                                       | Forms DNA adduct and induce apoptosis.                                                                          | [26]       |
| Carmustine                                        | DNA alkylating/crosslinking agent effective against glioma and other solid tumors.                              | [27]       |
| Chlorambucil                                      | Alkylates DNA; In leukemia cells induces apoptosis by p53dependent mechanism.                                   | [28]       |
| Cyclophosphamide (nitrogen mustard)               | Crosslinks DNA and causes strand breakage.                                                                      | [29]       |
| cisDiammineplatinum(II)<br>dichloride (Cisplatin) | Induces apoptosis by forming cytotoxic adducts with the DNA dinucleotide d(pGpG).                               | [30]       |
| Melphalan                                         | Forms DNA intrastrand crosslinks by alkylation of 5'(GGC) sequences.                                            | [31]       |
| Mitoxantrone                                      | Inhibits DNA synthesis by intercalating DNA.                                                                    | [32]       |

Table 2: DNA intercalators/groove binding agents and their mode of action as anticancer agent.

| Name                                   | Mode of Action                                                                                                                                                                                               | References |
|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| (±)Amethopterin<br>(Methotrexate)      | Blocks thymidine biosynthesis via inhibition of dihydrofolate reductase (folic acid antagonist)                                                                                                              | [42]       |
| 3Amino1,2,4benzotriazine<br>1,4dioxide | Hypoxia activated antineoplastic agent                                                                                                                                                                       | [43]       |
| Aminopterin                            | Mechanism same as methotrexate but more potent.                                                                                                                                                              | [44]       |
| Cytosine- β D-arabinofuranoside        | Selective inhibitor of DNA synthesis.                                                                                                                                                                        | [45]       |
| 5-Fluoro5' deoxyuridine                | Inhibits proliferation of cancer cells transformed by HRas or Trk oncogenes                                                                                                                                  | [46]       |
| 5-Fluorouracil                         | Depletes dTTP and inhibits thymidylate synthetase; it forms nucleotides that can be incorporated into RNA and DNA and induces p53dependent apoptosis                                                         | [47]       |
| Ganciclovir                            | In suicide gene therapy of solid tumors, the gene for <i>Herpes</i><br><i>simplex</i> virus thymidine kinase is delivered to tumor cells and expressed, which in turn activates ganciclovir<br>cytotoxicity. | [48]       |
| Hydroxyurea                            | Blocks the synthesis of deoxynucleotides by inactivating ribonucleoside reductase resulting into inhibition of DNA synthesis and induction cell death.                                                       | [49]       |
| Mitomycin C                            | Inhibits DNA synthesis, nuclear division, and proliferation of cancer cells.                                                                                                                                 | [50]       |

Table 3: DNA synthesis inhibitors and their mode of action as anticancer agent.

it regulates different downstream target genes. In cancer therapy, the drugs that targets TFs are less known than inhibitor molecules targeting the signal transduction. Recently novel immunotherapies have been documented against some transcription factors. For example transcription factor WT-1 and PML-RARa are the targets for the treatment of leukemia and acute promyelocytic leukemia respectively [52,53]. Drugs that potentially target the transcription machinery include cyclin-dependent kinases (CDKs), RNA polymerases or components of associated transcriptional complexes. Inhibitor such as triptolide, that targets the general transcription factors TFIIH and JQ1 to inhibit BRD4 are administered to target the high proliferative rate of cancer cells [54]. Tumor suppressor genes or oncogene antagonists have been used as an attempt at cancer therapy targeting TFs. It is reported that ETS transcription factors, especially Ets-1 have capability to inhibit cell growth, metastasis and tumor angiogenesis. But no reports are available regarding trials of gene therapies targeting ETS transcription factors. Considering that TFs that regulate growth, apoptosis, angiogenesis, invasion and metastasis related genes in tumor cells could be molecular targets for cancer gene therapy [54]. Some examples of transcription regulators are shown in Table 4.

## **Enzyme Inhibitors**

In contrast to normal cells, the metabolic properties of cancer cells are different and they depend on aerobic glycolysis for their energy requirement. In addition they have dysregulated fatty acid synthesis, Warburg-like glucose metabolism and glutaminolysis. Studies have shown that several enzymes in metabolic pathways act as anticancer targets and their inhibition is responsible for mediating apoptotic death in cancer cells. Hence inclusion of inhibitors of metabolic enzymes (e.g. glucose transporters, fatty acid synthase, hexokinase, lactate dehydrogenase A, pyruvate kinase M2, pyruvate dehydrogenase kinase and glutaminase etc.) in cancer therapy regimen are also important to enhance the efficacy of chemo/radiotherapy [60]. Estrogens and its receptors (ERs) are known to play important role in the progression and development of breast cancer [61-62]. Estrogens influence breast cancer through the ERa pathway, increases genetic mutations, and/or effects on DNA repair pathway [63,64]. Biosynthesis of estrogens from androgens involves a cytochrome P450 enzyme known as aromatase, encoded by the aromatase gene CYP19. Its expression is regulated by tissue-specific promoters [65]. It has been found in all the tissues in body including breast, brain, skin bone and muscles. It is found that the expression of aromatase is increased many folds in breast cancer tissues. Inhibition of this enzyme has been shown to be responsible for the decreased level of estrogen. Thus in the progression and development of hormone responsive breast cancers aromatase enzyme may have significant effects and their inhibitors (AI) can be utilized as chemopreventive agent [66]. AIs can be divided into steroidal (Type I inhibitors) or nonsteroidal (Type II inhibitors). Type I inhibitors binds covalently while type II binds reversibly to the aromatase enzyme. Amino glutethimide (Ist generation); formestane and vorozole (IInd generation); anastrozole, letrozole, and exemestane (III<sup>rd</sup> generation) are some examples of AIs. Testolactone, a first generation AI and is approved for treatment of advanced breast cancer in the United States [67]. Due to the development of resistance to AIs there is need to develop new aromatase inhibitors that could offer less severe sideeffects and increased clinical efficacy. Unwinding and rewinding of the DNA helix during various processes such as replication, repair, and chromatin remodeling, entanglement of DNA occurs. The enzyme DNA topoisomerases a nature's tool solve the problem by performing topological transformations in DNA. They form a covalent adduct with DNA resulting into a transient DNA break through which strand passage can occur. The two types of topoisomerases i.e., type I and type II enzymes involves a nucleophilic attack of a DNA phosphodiester

| Name              | Mode of Action                                                                                                                        | References |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------|------------|
| Actinomycin D     | Inhibits cell proliferation by forming complex with DNA and blocks production of mRNA (RNA polymerase inhibition); Induces apoptosis. | [55]       |
| Daunorubicin      | Complexes to DNA and blocks production of mRNA by RNA polymerase.                                                                     | [56]       |
| Doxorubicin       | Inhibits reverse transcriptase and RNA polymerase by binding to DNA.                                                                  | [57]       |
| Homoharringtonine | Binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation.                    | [58]       |
| Idarubicin        | Antileukemia agent with higher DNA binding capacity and greater cytotoxicity than daunorubicin                                        | [59]       |

Table 4: Transcription regulators and their mode of action as anticancer agent.

| Name                                               | Mode of Action                                                                                                                                                                                                                               | References |
|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| S(+)Camptothecin                                   | Binds irreversibly to the DNA topoisomerase I complex leading to the irreversible cleavage of DNA and the destruction of cellular topoisomerase I by the ubiquitin proteasome pathway. Induces apoptosis in many normal and tumor cell lines | [72]       |
| Curcumin                                           | Potent inhibitor of protein kinase C, EGFR tyrosine kinase and IkB kinase. Induces apoptosis in cancer cells.                                                                                                                                | [73]       |
| Deguelin                                           | Inhibitor of activated Akt. Does not affect MAPK, ERK1/2 or JNK.                                                                                                                                                                             | [74]       |
| Etoposide                                          | Binds to the DNA topoisomerase II complex to enhance cleavage and inhibit religation; inhibits synthesis of the oncoprotein Mdm2 and induces apoptosis in tumor lines that over express Mdm2.                                                | [75]       |
| Formestane                                         | Aromatase inhibitor                                                                                                                                                                                                                          | [76]       |
| Fostriecin                                         | Interferes with the reversible phosphorylation of proteins that are critical for progression through the cell cycle.                                                                                                                         | [77]       |
| Hispidin                                           | Potent inhibitor of protein kinase Cβ.                                                                                                                                                                                                       | [78]       |
| 2lmino1imidazolidineacetic<br>Acid (Cyclocreatine) | Creatine analog; decreases the rate of ATP production via<br>creatine kinase and reduces the proliferation of tumor cell lines characterized by high levels of creatine kinase<br>expression.                                                | [79]       |
| Mevinolin                                          | Inhibits mevalonic acid production and induces apoptosis in numerous cancer cell lines, perhaps, in part, by inhibiting the isoprenylation of Rhofamily GTPases.                                                                             | [80]       |
| Trichostatin A                                     | Histone deacetylase inhibitor that enhances the cytotoxic efficacy of anticancer drugs that target DNA.                                                                                                                                      | [81]       |

Table 5: Enzyme modulators and their mode of action as anticancer agent.

bond by a tyrosyl residue [68]. Type I enzyme is composed of N-terminal, core, linker and the C-terminal domains [69-71]. Different natural and synthetic molecules are known to target DNA topoisomerases represents the important class of antitumor drugs. The transesterification reaction involved in cleavage and relegation of DNA backbone is exploited by cytotoxic agents. Table 5 shows example of some enzyme modulators used as anticancer agents.

## **Gene Regulation**

Epigenetic alterations in DNA are potentially reversible and hence are involved in the earliest steps of malignant transformation. Interventions using epigenetically active compounds are considered as promising targets for anti-cancer therapy [82,83]. Beside these a number of challenges remain prior to any epigenetic intervention against cancer. Massive deregulation of the epigenetic machinery including DNA methylation, histone modifications and non-coding RNAs contributes to all major cancer hallmarks [84]. In eukaryotic cells acetylation and deacetylation of histones is an important event for transcriptional regulation for which histone acetyltransferase (HATs) and histone deacetylases (HDACs) are responsible, respectively [85]. Acetylation to lysine group of chromatin produces relaxation which intern allows increased transcription of the gene. On the other hand deacetylation increases condensation of chromatin thereby decreasing the rate of transcription of particular part of the chromatin [86,87]. It is found that HDACs are over expressed in tumors and this inhibits expressions of tumor suppressor genes. Thus HDACs inhibition may be considered as a potential strategy for cancer treatment. Vorinostat and romidepsin are the two HDAC inhibitors that have been approved by the FDA (US Food and Drug Administration) as anticancer therapeutic [88,89]. Metal-binding compounds such as clioquinol (a zinc ionophore) are increasingly believed to be an important group of anticancer agents. It has been reported that clioquinol induces apoptosis by the inhibition of NF-KB signaling pathway in human cancer cells [90]. Clioquinol targets cyclin D1 gene at both transcriptional and post-transcriptional regulation level in cancer cells. It is believed that clioquinol promotes mRNA degradation of the cyclin D1 gene regulated by miR-302C. This implies that metal-binding compounds might affect gene expression at different regulatory levels. Out of which the post-transcriptional gene regulation may be a potential target for chemotherapy [91]. P-glycoprotein (P-gp) is a transmembrane permeability glycoprotein and member of ABC super family (ATP binding cassette). It functions as a carrier mediated primary active efflux transporter and widely distributed throughout the body. P-gp is encoded by MDR1/ABCB1 gene and was firstly identified in human cancer cells. It was found to be present in pancreas, elementary canal, kidney, capillary endothelial cells of blood brain barrier and in various other tissues like lungs, heart, adrenals, spleen and skeletal muscle [92]. The optimal P-gp expression is always required for its protective function as its over expression leads to multi drug resistance while toxic reactions occurs because of its low expression level [93]. In various cancers a correlation was found between increased P-gp expression and MDR1 gene mRNA transcription which shows its connection to MDR in cancer. A few novel antitumor drugs which are able to suppress P-gp expression are under development. Lanthanum, a new anticancer compound have been reported to block P-gp expression especially in MDR cancerous cells [94]. Gefitinib another compound is a selective tyrosine kinase inhibitor has capability to inhibited P-gp function and has been used in the treatment of lung cancer [95]. Some of the gene regulator and their targets are shown in Table 6.

## **Microtubule Inhibitors**

Microtubules a component of cytoskeleton is composed of  $\alpha$  and  $\beta$  tubulin. This heterodimer is involved in many biological process *viz.*, cell signaling, cytokinesis, intracellular transport, maintenance of cell shape, and polarity [104]. Due to their role in mitosis they become an important target for anticancer drug development. In eukaryotes during cell division mitotic spindle is responsible for the movement of chromosomes to the opposite sides of the cell. These mitotic spindles are nothing but are composed of microtubules having tubulin as its monomer [105-107]. Molecules that interfere with microtubule assembly are known as microtubule inhibiting agents. Currently these agents are used in clinical therapy as they are able to suppress

| Name                            | Mode of Action                                                                                                                                                                                         | References |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 5-Aza2' -deoxycytidine          | Causes DNA demethylation or hemidemethylation, creating openings that allow transcription factors to bind to DNA and reactivate tumor suppressor genes.                                                | [96]       |
| Cholecalciferol<br>(Vitamin D3) | Antiproliferative action on breast, prostate, and colon cancer cells                                                                                                                                   | [97]       |
| 4-Hydroxytamoxifen              | Metabolite of tamoxifen that is a potent selective estrogen response modifier (SERM); the trans (Z) isomer has efficacy against estrogen sensitive cancers. The cis (E) isomer is an estrogen agonist. | [98]       |
| Melatonin                       | Enhances apoptotic death of cancer cells; inhibits proliferation/metastasis of breast cancer cells by inhibiting estrogen receptor action.                                                             | [99]       |
| Mifepristone                    | Progesterone receptor antagonist; stimulates prolactin secretion. Pgp inhibitor.                                                                                                                       | [100]      |
| Raloxifene                      | Selective estrogen response modifier (SERM), may have efficacy against estrogensensitive cancers.                                                                                                      | [101]      |
| Tamoxifen                       | Selective estrogen response modifier (SERM), used therapeutically and prophylactically against estrogen sensitive tumors.                                                                              | [102]      |
| Troglitazone                    | Antitumor agent; PPARy agonist; induces apoptosis via a p53 pathway.                                                                                                                                   | [103]      |

Table 6: Gene regulators and their mode of action as anticancer agent.

| Name                       | Mode of Action                                                                                                                                                                                           | References |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Colchicine                 | Antimitotic agent that disrupts microtubules by binding to tubulin and preventing its polymerization; induces apoptosis in several normal and tumor cell lines.                                          | [113]      |
| Dolastatin 15              | Reported to interact with tubulin and induce apoptosis                                                                                                                                                   | [114]      |
| Nocodazole                 | Antimitotic agent that binds to β tubulin and disrupts mitotic spindle function; Induces apoptosis in several normal and tumor cell lines.                                                               | [115]      |
| Paclitaxel                 | Binds to $\beta$ tubulin and promotes the formation of highly stable microtubules that resist depolymerization, preventing cell division.                                                                | [116]      |
| Podophyllotoxin            | Inhibits microtubule assembly.                                                                                                                                                                           | [117]      |
| Rhizoxin                   | Binds to $\beta$ tubulin in most eucaryotic cells including animals, plants and fungi. It completely prevents formation of an intrachain crosslink in $\beta$ tubulin by N,N'ethylenebis(iodoacetamide). | [118]      |
| Vinblastine                | Antimitotic agent. Inhibits microtubule assembly by binding tubulin and inducing self association; depolymerizes preexisting microtubules. Induces apoptosis in several tumor cell lines.                | [119]      |
| Vinorelbine<br>(Navelbine) | Potent antimitotic, antitumor agent. Low neurotoxicity is related to its higher affinity for mitotic microtubules than for axonal microtubules.                                                          | [119]      |

Table 7: Microtubule inhibitors and their mode of action as anticancer agent.

microtubule dynamics in fast dividing tumor cells by misdirecting the formation of a functional mitotic spindle. Due to this G2-M phase cell arrest occurs which leads to apoptosis of the tumor cells. According to their mode of action, microtubule inhibitors (MI) may be classified as stabilizing and destabilizing agents. Microtubule stabilizing agent (MSA) acts by promoting polymerization and microtubule polymer mass in cells. Taxanes (paclitaxel and docetaxel) and epothilones are the examples of MSA. They occupy the binding site in the  $\beta$ -subunit of tubulin that lies on the interior surface of microtubules. Their binding results into the stabilization and suppression of microtubule dynamics leading to G2/M phase cell cycle arrest and ultimately, apoptosis. On the other hand microtubule destabilizing agents (vinca alkaloids) inhibit polymerization and decrease polymer mass [108]. The MIs that binds to colchicine, vinblastine and paclitaxel binding sites on tubulin are known for their potent anticancer activity and are the most commonly prescribed antitumor agents [109]. There are limitations for the clinical use of other microtubule targeting drugs as they are known to involve in drug resistance emergence and intolerable toxicity. The researches are going on to discover and develop novel chemotherapeutic microtubule inhibitor agents having lower drug resistance and tolerable toxicity [108,110,111]. Colchicine is a branded drug for the treatment of several diseases such as Gout and Familial Mediterranean fever. Although there is a need to further characterize its effectiveness and side effects in the case of cancer treatment. 2-Amino-4-phenyl-4H-chromene-3-carboxylate a new class of novel microtubule-targeting agent with promising antitumor activity was recently developed. This molecule targets the potential colchicines binding site and induces apoptotic pathway [112-119]. Table 7 shows examples of microtubule inhibitors used as anticancer agent.

## Conclusion

The modulation of angiogenesis, DNA (synthesis, transcription and translation), enzyme activity and microtubule inhibition remains

an important therapeutic strategy against numerous diseases, including cancer. The current arsenal of anticancer agents targeting DNA or RNA activity is generally based upon their inhibitory activity against synthesis, transcription factors and enzymes. Besides effectiveness, vast majority of such anticancer agents exhibit lack of selectivity and are involved in drug resistance. This will limit the effectiveness of anticancer drugs. However, new therapeutic approaches that are currently being developed to circumvent these complications may definitely lead to discover novel anticancer drugs having low toxicity and resistance.

#### Acknowledgement

SK acknowledges Indian Council of Medical Research for providing financial support in the form of Research Associate fellowship.

#### References

- 1. Chabner BA, Roberts TG Jr (2005) Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5: 65-72.
- Schwartsmann G, Winograd B, Pinedo HM (1988) The main steps in the development of anticancer agents. Radiother Oncol 12: 301-313.
- Saijo N, Tamura T, Nishio K (2003) Strategy for the development of novel anticancer drugs. Cancer Chemother Pharmacol 52 Suppl 1: S97-101.
- Dickerson RE, Drew HR, Conner BN, Wing RM, Fratini AV, et al. (1982) The anatomy of A-, B-, and Z-DNA. Science 216: 475-485.
- Saenger W (1984) Principles of Nucleic Acid Structure, Biochemical Education, Springer-Verlag, New York.
- Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2: 188-200.
- Paul A, Bhattacharya S (2012) Chemistry and biology of DNA-binding small molecules. Current Sci 102: 212-231.
- Clarke SJ, Sharma R (2006) Angiogenesis inhibitors in cancer mechanisms of action. Aust Prescr 29: 9–12.
- 9. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
- 10. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV (2005) Angiostatin's

molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 96: 242-261.

- 11. Giffin B F, McCann PP, Bitonti AJ, Bacchi CJ (1986) Polyamine Depletion Following Exposure to DL-a-Difluoromethylornithine Both In Vivo and In Vitro Initiates Morphological Alterations and Mitochondrial Activation in a Monomorphic Strain of Trypanosoma brucei brucei. J Protozool 33: 238–243.
- Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, et al. (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 98: 1024-1029.
- Zhang Y, Yeh JR, Mara A, Ju R, Hines JF, et al. (2006) A chemical and genetic approach to the mode of action of fumagillin. Chem Biol 13: 1001-1009.
- Ravindranath MH, Muthugounder S, Presser N, Viswanathan S (2004) Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546: 121-165.
- Ataie-Kachoie P, Badar S, Morris DL, Pourgholami MH (2013) Minocycline targets the NF-κB Nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer. Mol Cancer Res 11: 1279-1291.
- Stepczynska A, Lauber K, Engels IH, Janssen O, Kabelitz D, et al. (2001) Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene 20: 1193-1202.
- 17. Aragon-Ching JB, Li H, Gardner ER, Figg WD (2007) Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov 2: 167-174.
- 18. Lerman LS (1961) Structural considerations in the interaction of DNA and acridines. J Mol Biol 3: 18-30.
- Goftar MK, Kor NM, Kor ZM (2014) DNA intercalators and using them as anticancer drugs. Int J Adv Biol Biom Res 2: 811-822.
- 20. Snyder RD (2007) Assessment of atypical DNA intercalating agents in biological and in silico systems. Mut Res 623: 72-82.
- Snyder RD, McNulty J, Zairov G, Ewing DE, Hendry LB (2005) The influence of N-dialkyl and other cationic substituents on DNA intercalation and genotoxicity. Mut Res 578: 88-99.
- 22. Chaires JB1 (1997) Energetics of drug-DNA interactions. Biopolymers 44: 201-215.
- Kapur A, Beck JL, Sheil MM (1999) Observation of daunomycin and nogalamycin complexes with duplex DNA using electrospray ionisation mass spectrometry. Rapid Commun Mass Spectrom 13: 2489-2497.
- 24. Bischoff G, Hoffmann S (2002) DNA-binding of drugs used in medicinal therapies. Curr Med Chem 9: 312-348.
- 25. Liu LV, Bell CB 3rd, Wong SD, Wilson SA, Kwak Y, et al. (2010) Definition of the intermediates and mechanism of the anticancer drug bleomycin using nuclear resonance vibrational spectroscopy and related methods. Proc Natl Acad Sci USA 107: 22419-22424.
- 26. Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46: 1972-1979.
- Schabel FM Jr (1976) Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep 60: 665-698.
- Nazarov AA, Meier SM, Zava O, Nosova YN, Milaeva ER, Hartinger CG, Dyson PJ (2015) Protein ruthenation and DNA alkylation: chlorambucil-functionalized RAPTA complexes and their anticancer activity. Dalton Trans 44: 3614-3623.
- 29. Emadi A, Jones RJ, Brodsky RA (2009) Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 6: 638-647.
- Florea AM, Busselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 3: 1351-1371.
- Hashim FJ, Shawkat MS, Aljewari H (2013) Anti-cancer effect of curcuma longa on leukemic cell lines evaluated by apoptosis and comet assay. Int J Pharm Pharm Sci 5; 671-674.
- Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3: 101-107.
- Nzila A1 (2006) The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother 57: 1043-1054.

- Hagner N, Joerger M (2010) Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2: 293-301.
- Julias JG, Pathak VK (1998) Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J Virol 72: 7941-7949.
- 36. Cerqueira NM, Fernandes PA, Ramos MJ (2007) Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents. Recent Pat Anticancer Drug Discov 2: 11-29.
- 37. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, et al. (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404: 42-49.
- Zhou B, Su L, Hu S, Hu W, Yip ML, et al. (2013) A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res 73: 6484-6493.
- Jordan A, Reichard P (1998) Ribonucleotide reductases. Annu Rev Biochem 67: 71-98.
- Kolberg M, Strand KR, Graff P, Andersson KK (2004) Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta 1699: 1-34.
- 41. Pereira S, Fernandes PA, Ramos MJ (2004) Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine. J Comput Chem 25: 1286-1294.
- 42. Uga H, Kuramori C, Ohta A, Tsuboi Y, Tanaka H, et al. (2006) A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol Pharmacol 70: 1832-1839.
- Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA (2003) Activation of 3-amino-,2,4-benzotriazine ,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 125: 748-756.
- 44. Werkheiser WC (1963) The biochemical, cellular, and pharmacological action and effects of the folic acid antagonists. Cancer Res 23: 1277-1285.
- Garcia-Diaz M, Murray MS, Kunkel TA, Chou KM (2010) Interaction between DNA Polymerase lambda and anticancer nucleoside analogs. J Biol Chem 285: 16874-16879.
- 46. Roobol C, De Dobbeleer GB, Bernheim JL (1984) 5-fluorouracil and 5-fluoro-2'deoxyuridine follow different metabolic pathways in the induction of cell lethality in L1210 leukaemia. Br J Cancer 49: 739-744.
- Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
- 48. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA (1999) Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 59: 3861-3865.
- Gao W, Lam W, Zhong S, Kaczmarek C, Baker DC, et al. (2004) Novel mode of action of tylophorine analogs as antitumor compounds. Cancer Res 64: 678-688.
- Paz MM, Zhang X, Lu J, Holmgren A (2012) A new mechanism of action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase. Chem Res Toxicol 25: 1502-1511.
- Mees C, Nemunaitis J, Senzer N (2009) Transcription factors: their potential as targets for an individualized therapeutic approach to cancer. Cancer Gene Ther 16: 103-112.
- Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, et al. (2000) Cancer immunotherapy targeting Wilms' tumor gene WT1 product. J Immunol 164: 1873-1880.
- Padua RA, Larghero J, Robin M, le Pogam C, Schlageter MH, et al. (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 9: 1413-1417.
- 54. Villicana C, Cruz G, Zurita M1 (2014) The basal transcription machinery as a target for cancer therapy. Cancer Cell Int 14: 18.
- Koba M, Konopa J (2005) [Actinomycin D and its mechanisms of action]. Postepy Hig Med Dosw (Online) 59: 290-298.
- Preobrazhenskaya MN, Tevyashova AN, Olsufyeva EN, Huang KF, Huang HS (2006) Second generation drugs-derivatives of natural antitumor anthracycline antibiotics daunorubicin, doxorubicin and carminomycin. J Med Sci 26: 119-128.
- 57. Cutts SM, Nudelman A, Rephaeli A, Phillips DR (2005) The power and potential of doxorubicin-DNA adducts. IUBMB Life 57: 73-81.

- Nirmala MJ, Samundeeswari M, Sankar PD (2011) Natural plant resources in anti-cancer therapy-A review. Res Plant Biol 3: 1-14.
- Majsterek I, Gloc E, Blasiak J, Reiter RJ (2005) A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J Pineal Res 38: 254-263.
- 60. Zhao Y, Butler EB, Tan M (2013) Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 4: e532.
- Kuller LH, Matthews KA, Meilahn EN (2000) Estrogens and women's health: interrelation of coronary heart disease, breast cancer and osteoporosis. J Steroid Biochem Mol Biol 74: 297-309.
- 62. Pfaff DW, Vasudevan N, Kia HK, Zhu YS, Chan J, et al. (2000) Estrogens, brain and behavior: studies in fundamental neurobiology and observations related to women's health. J Steroid Biochem Mol Biol 74: 365-373.
- Osborne CK, Schiff R, Fuqua SA, Shou J (2001) Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 7: 4338s-4342s.
- 64. Bhat KP, Pezzuto JM (2001) Natural modulators of estrogen biosynthesis and function as chemopreventive agents. Arch Pharm Res 24: 473-484.
- 65. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD (2008) Natural products as aromatase inhibitors. Anticancer Agents Med Chem 8: 646-682.
- 66. Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, et al. (2006) Secondand third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 94: 1789-1796.
- 67. Cocconi G (1994) First generation aromatase inhibitors--aminoglutethimide and testololactone. Breast Cancer Res Treat 30: 57-80.
- Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70: 369-413.
- Stewart L, Ireton GC, Champoux JJ (1996) The domain organization of human topoisomerase I. J Biol Chem 271: 7602-7608.
- Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279: 1504-1513.
- Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ (1998) A model for the mechanism of human topoisomerase I. Science 279: 1534-1541.
- Tesauro C, Morozzo della Rocca B, Ottaviani A, Coletta A, Zuccaro L, et al. (2013) Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico. Mol Cancer 12: 100.
- Shishodia S (2013) Molecular mechanisms of curcumin action: gene expression. Biofactors 39: 37-55.
- 74. Thamilselvan V, Menon M, Thamilselvan S (2011) Anticancer efficacy of deguelin in human prostate cancer cells targeting glycogen synthase kinase-3 β/β -catenin pathway. Int J Cancer 129: 2916-2927.
- van Maanen JM, Retel J, de Vries J, Pinedo HM (1988) Mechanism of action of antitumor drug etoposide: a review. J Natl Cancer Inst 80: 1526-1533.
- Noberasco C, Bajetta E, Zilembo N, Di Leo A, Cappuzzo F, et al. (1995) Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Oncol 52: 454-457.
- Roberge M, Tudan C, Hung SM, Harder KW, Jirik FR, et al. (1994) Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 54: 6115-6121.
- Lim JH, Lee YM, Park SR, Kim da H, Lim BO (2014) Anticancer activity of hispidin via reactive oxygen species-mediated apoptosis in colon cancer cells. Anticancer Res 34: 4087-4093.
- Kornacker M, Schlattner U, Wallimann T, Verneris MR, Negrin RS, et al. (2001) Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis. Int J Cancer 94: 513-519.
- Chorawala MR, Oza PM, Shah GB (2012) Mechanisms of anticancer drugs resistance: An overview. IJPSDR I4: 1-09.
- Roh MS, Kim CW, Park BS, Kim GC, Jeong JH, et al. (2004) Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells. Apoptosis 9: 583-589.
- 82. Florean C, Schnekenburger M, Grandjenette C, Dicato M, Diederich M (2011)

Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 3: 581-609.

- 83. Campbell RM, Tummino PJ (2014) Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest 124: 64-69.
- Schnekenburger M, Diederich M (2014) Modulation of epigenetic mechanisms for anti-cancer intervention–new challenges and perspectives. Austin J Genet Genomic Res 1: 1-2.
- Lehrmann H, Pritchard LL, Harel-Bellan A (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86: 41-65.
- Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074-1080.
- Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
- Campas-Moya C1 (2009) Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) 45: 787-795.
- Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247-1252.
- Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE (2005) Anticancer activity of the antibiotic clioquinol. Cancer Res 65: 3389-3395.
- Zheng J, Benbrook DM, Yu H, Ding WQ (2011) Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms. Anticancer Res 31: 2739-2747.
- Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, et al. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738.
- Srivalli KMR, Lakshmi PK (2012) Overview of P-glycoprotein inhibitors: a rational outlook. Braz J Pharmaceut Sci 48: 354-367.
- Heffeter P, Jakupec MA, Korner W, Chiba P, Pirker C, et al. (2007) Multidrugresistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol 73: 1873-1886.
- 95. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, et al. (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49: 337-343.
- Christman JK (2002) 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483-5495.
- Krishnan AV, Feldman D (2011) Mechanisms of the anti-cancer and antiinflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 51: 311-336.
- Monteiro JP, Martins JD, Luxo PC, Jurado AS, Madeira VM (2003) Molecular mechanisms of the metabolite 4-hydroxytamoxifen of the anticancer drug tamoxifen: use of a model microorganism. Toxicol In Vitro 17: 629-634.
- 99. Di Bella G, Mascia F, Gualano L, Di Bella L (2013) Melatonin anticancer effects: review. Int J Mol Sci 14: 2410-2430.
- 100.Yu S, Yang X, Zhu Y, Xie F2, Lu Y, et al. (2015) Systems pharmacology of mifepristone (RU486) reveals its 47 hub targets and network: comprehensive analysis and pharmacological focus on FAK-Src-Paxillin complex. Sci Rep 5: 7830.
- 101.Ho Sui SJ, Lo R, Fernandes AR, Caulfield MD, Lerman JA, et al. (2012) Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. Int J Antimicrob Agents 40: 246-251.
- 102. Monteiro JP, Martins JD, Luxo PC, Jurado AS, Madeira VM (2003) Molecular mechanisms of the metabolite 4-hydroxytamoxifen of the anticancer drug tamoxifen: use of a model microorganism. Toxicol In Vitro 17: 629-634.
- 103.Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM, et al. (2008) Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol 14: 2168-2173.
- 104. Hall A (2009) The cytoskeleton and cancer. Cancer Metastasis Rev 28: 5-14.
- 105. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
- 106. Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8: 413-450.

- 107. Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9: 790-803.
- 108. Perez EA (2009) Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8: 2086-2095.
- 109.Carlson RO (2008) New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs 17: 707-722.
- 110. Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14: 7167-7172.
- 111. Gascoigne KE, Taylor SS (2009) How do anti-mitotic drugs kill cancer cells? J Cell Sci 122: 2579-2585.
- 112. Xi J, Zhu X, Feng Y, Huang N, Luo G, et al. (2013) Development of a novel class of tubulin inhibitors with promising anticancer activities. Mol Cancer Res 11: 856-864.
- 113. Lin ZY, Wu CC, Chuang YH, Chuang WL (2013) Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci 93: 323-328.

- 114. Lopus M (2013) Mechanism of mitotic arrest induced by dolastatin 15 involves loss of tension across kinetochore pairs. Mol Cell Biochem 382: 93-102.
- 115. Singh P, Rathinasamy K, Mohan R, Panda D (2008) Microtubule assembly dynamics: an attractive target for anticancer drugs. IUBMB Life 60: 368-375.
- 116. AL-Sharif MMZ (2012) Studies on the Genotoxic Effects of Anticancer Drug Paclitaxel (Taxol) in Mice. World Appl Sci J 16: 989-997.
- 117. Nagar N, Jat RK, Saharan R, Verma S, Sharma D, Bansal K (2011) Podophyllotoxin and their glycosidic derivatives. Pharmacophore 2: 124-134.
- 118. Behrangi N, Hashemi M, Borna H, Akbarzadeh A (2012) Microtubules and tubulins as target for some natural anticancer agents extracted from marines, bacteruim, and fungus. Adv Studies in Biol 4: 1-9.
- 119. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA (2001) Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 60: 225-232.